Valiant Organics Subsidiary Files SEBI IPO Papers

JSW Infra IPO attracts ₹1,260 Cr from anchor investors before launch

Valiant Laboratories, a subsidiary of Valiant Organics specializing in material production, has recently submitted a draft red herring prospectus to the Securities and Exchange Board of India (SEBI), the country’s capital markets regulator.

The purpose of this filing is to initiate an initial public offering (IPO) and raise funds. The draft papers, dated June 5, outline the company’s plans to issue up to 1,15,56,000 equity shares through a fresh offering. Valiant Laboratories intends to list these shares on both the BSE Limited and the National Stock Exchange of India.

As an active pharmaceutical ingredient (API) manufacturing firm, Valiant Laboratories primarily focuses on producing paracetamol. Their expertise lies in the manufacturing process of this essential pharmaceutical component.

On June 6, Valiant Organics’ share price experienced a 1 percent increase, settling at Rs 609.95 on the BSE.

About Valiant Organics:

Valiant Organics Limited is an Indian chemical manufacturing company that specializes in the production and distribution of various specialty chemicals. The company offers a diverse range of products, including agrochemicals, dyes, pigments, pharmaceuticals, cosmetics, specialty chemicals, polymers, and veterinary products.

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *